|1.||Knight, Linda C: 2 articles (09/2004 - 09/2004)|
|2.||Romano, Jan E: 1 article (09/2004)|
|3.||Welch, Michael J: 1 article (09/2004)|
|4.||Lin, Kuo-Shyan: 1 article (09/2004)|
|5.||Gabriel, Jerome L: 1 article (09/2004)|
|6.||Baidoo, Kwamena E: 1 article (09/2004)|
|7.||McQuade, Paul: 1 article (09/2004)|
|8.||Knight, L C: 1 article (06/2000)|
|9.||Romano, J E: 1 article (06/2000)|
|10.||Baidoo, K E: 1 article (06/2000)|
09/01/2004 - "To see if tumor uptake could be improved upon, (64)Cu was tethered to bitistatin using bromoacetamidobenzyl-1,4,7,10-tetraazacyclododecane-N,N',N' ',N' "-tetraacetic acid (BAD). "
09/01/2004 - "To determine whether radiolabeled bitistatin could target tumors, its biodistribution was tested in tumor-bearing mice. "
09/01/2004 - "As with (125)I-labeled bitistatin, the (64)Cu conjugate showed a 50% reduction in tumor uptake with the co-injection of 200 microg of unlabeled bitistatin (0.8 +/- 0.2 %ID/g). "
09/01/2004 - "Co-injection of 200 microg of unlabeled bitistatin reduced tumor uptake 62%, suggesting that the binding of (125)I-bitistatin is receptor-mediated. "
09/01/2004 - "Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis."
06/01/2000 - "Hn-bitistatin was labeled by incubation with 99mTc-glucoheptonate to 96 TBq/mmol and then tested for binding to platelets in vitro and for imaging of 24-h-old DVT and PE in a canine model used previously for other thrombus tracers. "
12/25/1989 - "In order to assess the antithrombotic potential of bitistatin, a canine model of platelet-dependent coronary thrombus formation was utilized. "
|3.||Venous Thrombosis (Deep-Vein Thrombosis)
07/01/1990 - "The effect of tissue-type plasminogen activator (t-PA) alone or in combination with heparin, the Arg-Gly-Asp-containing peptide bitistatin, or both heparin and bitistatin was evaluated on thrombolysis time and acute reocclusion in a canine model of coronary thrombosis. "
07/01/1990 - "Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis."
|2.||Tissue Plasminogen Activator (Alteplase)